TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07780669: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study of the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants 40 to 80 Years of Age With Moderate to Very Severe COPD (PERSIST

Sponsor: GlaxoSmithKline · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 624 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07780669 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07780669 Rescue Dossier →